GH Research PLC (NASDAQ:GHRS - Get Free Report)'s share price was up 2% on Wednesday . The stock traded as high as $9.80 and last traded at $9.80. Approximately 1,026 shares traded hands during trading, a decline of 99% from the average daily volume of 79,340 shares. The stock had previously closed at $9.61.
Wall Street Analyst Weigh In
Several equities research analysts have commented on the stock. Canaccord Genuity Group decreased their price objective on shares of GH Research from $31.00 to $28.00 and set a "buy" rating for the company in a research note on Monday. JMP Securities reiterated a "market outperform" rating and set a $39.00 price target on shares of GH Research in a report on Wednesday, September 4th. Finally, HC Wainwright restated a "buy" rating and issued a $40.00 price objective on shares of GH Research in a research note on Wednesday.
View Our Latest Analysis on GHRS
GH Research Trading Up 8.2 %
The company has a market cap of $541.09 million, a P/E ratio of -12.41 and a beta of 0.74. The business's fifty day moving average is $7.82 and its 200 day moving average is $10.33.
GH Research (NASDAQ:GHRS - Get Free Report) last released its quarterly earnings data on Tuesday, September 3rd. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.03. As a group, research analysts expect that GH Research PLC will post -0.85 EPS for the current fiscal year.
Institutional Inflows and Outflows
A hedge fund recently raised its stake in GH Research stock. RA Capital Management L.P. grew its position in shares of GH Research PLC (NASDAQ:GHRS - Free Report) by 1.3% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,686,689 shares of the company's stock after purchasing an additional 85,000 shares during the period. RA Capital Management L.P. owned approximately 12.85% of GH Research worth $44,734,000 at the end of the most recent quarter. 56.90% of the stock is owned by institutional investors and hedge funds.
About GH Research
(
Get Free Report)
GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider GH Research, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GH Research wasn't on the list.
While GH Research currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
